Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed EBT Margin for 6 consecutive years, with 1505.0% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 376792.0% to 1505.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 260.1% through Dec 2025, up 297770.0% year-over-year, with the annual reading at 260.1% for FY2025, 298504.0% up from the prior year.
  • EBT Margin hit 1505.0% in Q4 2025 for Insight Molecular Diagnostics, up from 4249.23% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 2006.4% in Q1 2023 to a low of 11752.17% in Q3 2024.
  • Historically, EBT Margin has averaged 2383.8% across 5 years, with a median of 1656.19% in 2023.
  • Biggest five-year swings in EBT Margin: soared 5414713bps in 2021 and later crashed -1023959bps in 2024.
  • Year by year, EBT Margin stood at 997.16% in 2021, then plummeted by -340bps to 4385.77% in 2022, then decreased by -17bps to 5152.55% in 2023, then skyrocketed by 56bps to 2262.92% in 2024, then soared by 167bps to 1505.0% in 2025.
  • Business Quant data shows EBT Margin for IMDX at 1505.0% in Q4 2025, 4249.23% in Q3 2025, and 1900.0% in Q2 2025.